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ABSTRACT 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by 
inflammation of the synovial membrane that can lead to joint deformity and physical 
disability. Despite recent progress in the therapeutic field of RA, the exact molecular 
mechanisms responsible for chronic joint inflammation are not yet completely 
understood. The overall aim of this thesis was to identify new molecular mechanisms 
responsible for inflammation in the rheumatoid joint and to understand how distinct 
anti rheumatic drugs act upon these mechanisms. 
 
I first focused on validating arthroscopy as a research tool for better understanding of 
the molecular mechanisms of action of anti rheumatic drugs, demonstrating that 
rheumatologic arthroscopy is a safe method, with very few complications and allowing 
retrieval of representative tissue in clinical longitudinal studies. We also propose an 
easy to perform way to quantitate macroscopic joint changes based on photos acquired 
during arthroscopies.  
 
Based on our validation study we then used this method to perform several mechanisms 
of action studies. We first investigated the effect of etanercept on synovial expression 
of lymphotoxin-α (LT-α) and tumor necrosis factor-α (ΤΝF-α). As predicted from 
previous in vitro studies etanercept was able to decrease synovial expression of both 
LT-α and TNF-α. The effect was however limited to good clinical responders. We 
propose LT-α modulation as an additional but not essential mechanism to explain the 
clinical efficacy observed with this drug in clinical practice. 
 
Defective apoptosis of lymphocytes is linked to pathogenesis of RA and 
glucocorticoids are good in vitro inducers of lymphocyte apoptosis. We therefore 
investigated the effect of intra articular glucocorticoids on synovial apoptosis 
demonstrating that in the complex milieu of rheumatoid joint glucocorticoids actually 
fail to induce lymphocyte apoptosis. We further demonstrate that monocytes are 
essential in rescuing synovial T cells from glucocorticoid-induced apoptosis through a 
soluble factor mediated mechanism, a feature that is specific for RA-derived synovial 
lymphocytes. 
 
LL-37 is an anti microbial peptide belonging to the cathelicidin family with important 
functions in innate immune response but recently also implicated as a modulator of 
acquired immune responses. We therefore investigated a potential role for LL-37 in RA 
pathogenesis, demonstrating that the peptide is present at low levels in healthy 
synovium, but up regulated in the context of inflammation. We also identified synovial 
neutrophils and to a lesser extent macrophages as the main cell types expressing LL-37. 
Distinct modulation patterns of LL-37 by some but not all anti rheumatic drugs and 
correlation with local levels of inflammation suggest a potential direct contribution of 
LL-37 to synovial pathology in RA. 
 
In conclusion, we demonstrated that arthroscopy is a safe and reliable research tool for 
studies on mechanisms of action of anti rheumatic drugs and pathogenic traits of the 
inflamed rheumatoid joint. 
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1 BACKGROUND 
1.1 INNATE AND ADAPTIVE IMMUNITY 
The immune system defends us against microorganisms that can cause infection. To 
protect the individual effectively the immune system must fulfil four main tasks. First 
immunological recognition, the presence of an infection must be detected. This task is 
carried out by the leukocytes in the innate immune system, which provide an 
immediate response, and by the lymphocytes of the adaptive immune system. The 
second task is to contain the infection and if possible eliminate it completely. To do 
that we need immune effector functions such as the complement system of blood 
proteins, antibodies and the destructive capacities of leukocytes among them 
lymphocytes. At the same time the immune response must be kept under control so that 
it does not do damage to itself. Immune regulation, the ability of the immune system to 
self-regulate, is an important function of the immune response and failure of such 
regulation can cause autoimmune diseases like RA. The fourth task is to protect the 
individual against recurring infections due to the same pathogen and therefore the 
adaptive immunity has evolved the capacity of generating an immunological memory 
[1]. 
 
Innate immunity serves as a first line of defense. It works as an early barrier to 
pathogens that acts immediately but does not generate a lasting protective immunity. 
Key components of the innate immunity are anatomical barriers such as the epithelia of 
the skin, the gastro-intestinal and respiratory tracts and professional phagocytes like 
neutrophils, macrophages and dendritic cells. Phagocytes can engulf microbes and 
destroy and eliminate them by degrading enzymes and cytotoxic mediators like 
antimicrobial peptides (AMPs) and reactive oxygen species (ROS). AMPs are naturally 
occurring peptides considered to be among the earliest developed molecular effectors 
of innate immunity [2, 3]. The immune system is triggered by detection of pathogen 
(non-self) associated molecular patterns (PAMPs) or damage associated molecular 
patterns (DAMPs) from invading organisms or injured structures. The macrophages, 
neutrophils and dendritic cells have receptors to recognize these patterns, so called 
pattern recognition receptors (PRRs). The dendritic cells work as a bridge between 
innate and adaptive immunity. They capture the microbial antigen, migrate to 
peripheral lymphoid organs and use their major histocompatibility complex (MHC) 
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class II molecules to display the antigen, in conjunction with co-stimulatory signals, to 
T cells. This initiates the early events in adaptive immunity where antigen specific T 
and B cells are activated [1]. After activation they undergo clonal proliferation and 
maturation. These features allow the adaptive immune response to be directed towards 
specific pathogens. Subpopulations of these cells later become memory cells that can 
quickly mount an immune response to the same microbe when reactivated. 
Upon encounter with the antigen, clonal expansion of antigen-specific T and B cells 
occurs. The specificity of T and B cell receptors is acquired through gene translocation 
and mutations that allow an increase in affinity and specificity. Innate immune cells do 
recognize molecular motifs that are shared by various classes of microbes through 
genetically encoded PRRs, of which toll-like receptors (TLR) are a major family. TLRs 
are highly conserved across evolutionary time and serve to activate host defense 
through a signalling pathway that operates in most multicellular organisms. In 
vertebrates TLRs have a key role in enabling the initiation of adaptive immunity. TLR-
4 for example detects the presence of Gram-negative bacteria through its association 
with the peripheral membrane protein CD14, which is a receptor for bacterial 
lipopolysaccharide (LPS). Other TLRs respond to other molecular patterns found on or 
in pathogens. TLRs activate the transcription factor NFκβ, which then induces the 
transcription of a variety of genes, including cytokines, chemokines and co-stimulatory 
molecules that have essential roles in directing the course of the adaptive immune 
response. 
 
1.2 INFLAMMATION AND AUTOIMMUNITY 
Inflammation is our body´s response to injury and tissue damage. An acute 
inflammation as a response to an infection is a normal reaction that serves to remove 
the pathological agent and start healing and tissue repair. However the inflammation 
process itself may also contribute to the development of autoimmune diseases. The 
inflammatory pathway consists of inducers, sensors, mediators, and target tissues. 
Inducers initiate the inflammatory response and are detected by sensors. Sensors, such 
as TLRs, are expressed on cells present in the tissue like macrophages, dendritic cells 
and mast cells. They induce the production of mediators, including cytokines, 
chemokines, eicosanoids and products of proteolytic cascades. These inflammatory 
mediators act on various target tissues to develop changes in their functional status for 
optimizing adaptation to the infection or tissue injury, associated with the particular 
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inducers that elicited the inflammatory response [4]. Typical signs of inflammation are 
tumor (swelling), rubor (redness), calor (heat), dolor (pain), and functio laesa 
(decreased function). 
A typical example where inflammation contributes to disease development is in 
autoimmune diseases such as RA. Autoimmunity results from the failure of self-
tolerance like inability of lymphocytes to distinguish self from non-self, so that an 
immune response against the body´s own cells and tissues leading to chronic 
inflammation will occur. 
 
1.3 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by 
inflammation of the synovium, which outlines the inner cavity of synovial joints except 
for cartilage surfaces. It is a heterogeneous disease spanning several disease subsets 
with potential distinct pathogenic pathways [5-7]. Sir Alfred Garrod was in 1859 the 
first to define RA, even though the typical symptoms had been described far earlier [8]. 
Findings of population-based studies show that RA affects around 0.5–1.0% of adults 
in developed countries. The disease is two to three times more frequent in women than 
in men. The prevalence rises with age and is highest in women of 65 years and older 
[9]. The incidence ranges from 5 to 50 per 100 000 adults in developed countries and 
increases with age [10, 11]. The prevalence of RA varies geographically. The disease is 
more common in northern Europe and in the North of America compared with parts of 
the developing world, such as parts of the west of Africa [12-14]. Today it seems like 
the incidence of RA might be decreasing with onset later in life [15, 16]. 
RA is defined by a series of clinical criteria to ensure correct classification. A set of 
criteria, revised in 1987 by the American College of Rheumatology (ACR) (Table 1) 
was designed to help differentiate RA from other inflammatory arthritides [17]. These 
criteria were developed to define established disease and provide a standard for 
recruitment into clinical trials. Today we know more about the etiology and 
pathogenesis of RA and the importance of early diagnosis for the possibility of early 
aggressive treatment [5, 18]. To meet the need for earlier diagnosis and institution of 
effective disease-suppressing therapy to prevent or minimise the occurrence of the 
undesirable sequelae a new classification system was introduced, developed by the 
ACR and European League Against Rheumatism (EULAR) in 2010 [19] (Table 1). 
This new classification system redefines the current paradigm of RA by focusing on 
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features at earlier stages of disease that are associated with persistent and erosive 
disease, rather than defining the disease by its late-stage features like rheumatoid 
nodules and existent erosions. 
 
 
Table 1. ACR 1987 criteria (left panel) were designed to classify established rheumatoid arthritis. 2010 
ACR/EULAR criteria (right panel) are intended to classify both early and established disease. 
 
RA is a heterogeneous disease that probably should be divided into at least two 
different subsets with different causes and severity. Traditionally the subsets have been 
divided based on presence or absence of autoantibodies [5]. Rheumatoid factor (RF) is 
the classic autoantibody in RA. IgM and IgA RF are key pathogenic markers directed 
against the Fc fragment of IgG. Today more specific antibodies, so called anti 
citrullinated-proteins antibodies (ACPAs) [20], are used for the identification of clinical 
subsets of disease, with more relevance in classification of RA according to shared 
features in genetic and environmental risk factors. Both RF and ACPA are clinically 
useful prognostic markers and predict a more aggressive, destructive disease [21]. 
RA is a complex genetic disease and the exact cause is still not known but it is 
considered to develop when genetically predisposed individuals are exposed to specific 
environmental risk factors [22, 23]. These genetic and environmental risks factors 
interact and result in molecular events that drive development of arthritis. Twin studies 
implicate genetic factors in RA with concordance rates of 15 to 30% among 
monozygotic twins and 5% among dizygotic twins [24]. Estimated contribution of 
genetic factors for RA is around 50% [24]. 
ACR 1987 criteria
1. Morning sti!ness (at least 1h)
2. Arthritis of three or more joint areas
3. Arthritis of hand joints (≥1 swollen joints)
4. Symmetrical arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes (erosions)
Four of these seven criteria must be present.
Criteria 1-4 must have been present for at least 6 weeks
ACR/EULAR 2010 criteria
1. Joint involvement (0-5)
t0OFNFEJVNUPMBSHFKPJOU	

t5XPUPUFONFEJVNUPMBSHFKPJOUT	

t0OFUPUISFFTNBMMKPJOUT	MBSHFKPJOUTOPUDPVOUFE
	

t'PVSUPUFOTNBMMKPJOUT	MBSHFKPJOUTOPUDPVOUFE
	

t.PSFUIBOUFOKPJOUT	BUMFBTUPOFTNBMMKPJOU
	

2. Serology (0-3)
t/FHBUJWF3'BOEOFHBUJWF"$1"	

t-PXQPTJUJWF3'PSMPXQPTJUJWF"$1"	

t)JHIQPTJUJWF3'PSIJHIQPTJUJWF"$1"	

3. Acute-phase reactants (0-1)
t/PSNBM$31BOEOPSNBM&43	

t"COPSNBM$31PSBCOPSNBM&43	

4. Duration of symptoms (0-1)
t-FTTUIBOXFFLT	

tXFFLTPSNPSF	

Points are shown in parentheses. Cut-point for rheumatoid 
arthritis. 6 points or more. Patients can also be classi!ed as 
having rheumatoid arthritis if they have: a. typical erosions; 
b. long-standing disease previously satisfying the 
classi!cation criteria
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The strongest genetic risk factor for seropositive RA is linked to the MHC class II 
locus. The HLA-DRB1 alleles code for a common amino acid sequence, the shared 
epitope, located in the β chain of the HLA-DR molecule [25, 26]. This is a group of 
alleles that play an important role in antigen presentation by influencing the binding 
and presentation of arthritogenic peptides to autoreactive CD4+ T cells [27] There are 
also other genes involved such as PTPN22 [28], coding for tyrosine phosphatase 
involved in T cell and B cell signalling [29]. At present over 30 non-MHC risk alleles 
for ACPA positive RA have been identified and validated through candidate gene 
studies and GWAS [30]. 
Smoking is the dominant environmental risk factor for developing RA [31], particularly 
in RF positive and ACPA positive patients. A gene-environment interaction between 
smoking and shared epitope provides a high risk of ACPA+ RA but not ACPA- RA 
[32]. Other forms of bronchial stress, like silica exposure, increase the risk of RA 
among persons with susceptibility HLA DR4 alleles (reviewed in [33]). In a recent 
study overweight together with smoking was shown to be a risk factor for developing 
RA in a cohort of autoantibody positive individuals [34]. 
Several anti-rheumatic therapies are available today, either classic disease modifying 
anti rheumatic drugs (DMARD) with a broad non specific immune modulation effect or 
modern biologicals, partly native human substances produced by gene technology that 
target specific molecule in the immune system. Despite this it is still difficult to find the 
best treatment for each patient right from the beginning and still there are few complete 
remissions and limited effects in about 30% of the patients. This is partly due to limited 
knowledge on the exact mechanisms of action of each individual anti rheumatic drug in 
distinct clinical settings. Particularly in RA this type of research is partially restricted 
due to difficulties in investigating the site of active inflammation, i.e. the inflamed 
synovium. I focused therefore my thesis on validating arthroscopy as a research tool for 
better understanding of the molecular mechanisms of action of anti rheumatic drugs. 
 
1.4 ARTHROSCOPY 
Historically synovial membrane biopsies have been retrieved from end stage 
destructive joints at the time of arthroplasty. However this type of intervention limits 
the investigations to late chronic destructive stages of the joint inflammation not 
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relevant in the search of early biomarkers. Later on blind needle biopsy was introduced 
which could be used to retrieve synovial tissue in any stage of active disease. This is a 
safe, cheap method easy to perform but restricted to larger joints and not reliable in 
getting accurate samples [35, 36]. During the last years ultrasound guided biopsies are 
increasingly used, this method can be performed in both small and large joints under 
local anaesthesia [37]. It allows an indirect visual inspection and the best biopsy site is 
selected based on synovial proliferation and vascularisation. The biopsies taken have 
been shown to be reliable for histopathological assessment [38, 39]. Although this is an 
appealing technique it has some disadvantages, the bony surfaces might cause 
ultrasonic disturbances, which might limit the access area and it is also difficult to look 
into non-inflammatory joints. Further validation of this method is needed. 
 
Arthroscopic biopsy have been used by rheumatologists since the late 1970’s and is 
technically more complicated but provides better possibilities in getting good samples 
as one has direct vision of the synovial membrane in both small and large joints [36]. 
Since the introduction of local and regional anaesthetics this procedure can be 
performed safely in an office based setting [40]. The arthroscopic procedure is well 
tolerated and safe [41]. In a survey, in which information from 15682 arthroscopies 
performed by rheumatologists was collected, a complication rate of haemarthrosis was 
0,9%, deep vein thrombosis 0,2% and wound and joint infection 0,1%. The total 
complication rate reported was 15.1/1000 arthroscopies, which is comparable to reports 
from orthopedic surgeons [40]. 
 
Several studies have addressed the issue of intra-articular variation of synovitis. Intra- 
articular variation has been confirmed macroscopically [42], microscopically for cells 
[43], protein expression [44] and gene expression [45]. In our studies we have 
developed a method where we take samples from maximum macroscopic active 
synovitis both distant and close to cartilage. When performing consecutive studies with 
repeated procedures we try to sample the biopsies close to the same sites as in the first 
procedure according to a specially arthroscopy map (study I). One study has shown that 
the inflammation in one inflamed joint is generally representative of that in other 
inflamed joints [46]. Therefore, it is possible to use serial samples from the same joint, 
selecting either large or small joints. Another study showed that biopsies taken from 
actively inflamed synovial tissues of patients with RA show expression of unique 
patterns of mRNA, provided that the biopsy has been taken in such a way that the 
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analysis is performed on cells from an inflamed site [47]. Both inter-individual and 
intra-individual variation must be taken into consideration when analysing gene 
expression in synovial tissue. Therefore sites of maximal inflammation and/or random 
sampling from multiple synovial sites should be considered. 
For research purposes synovial tissue can be processed for histology, immunohistology 
(IHC), immunofluorescence, in situ hybridization, PCR, micro-array, proteomics and 
cell or tissue culture. Immunohistochemistry can be performed on formalin fixed, 
paraffin-embedded material or on samples that have been snap-frozen in liquid 
nitrogen. 
A B 
 
Figure 1 
Arthroscopic images of a normal joint with thin transparent synovium (A) and a joint with on going 
inflammation (early RA) where we can see hypertrophied synovium with villi formation and increased 
vascularity (B). 
 
1.5 BASIC ASPECTS OF THE SYNOVIAL MEMBRANE 
The synovium is the central player in RA pathogenesis. A normal synovium (figure 1A) 
consists of two distinct layers, the lining or intimal layer and the sublining or subintimal 
layer. The lining layer is the superficial layer that is in contact with the intra-articular 
cavity and produces lubricious synovial fluid (SF). It is one to three cell-layers deep, 
containing macrophage-like type A synoviocytes and fibroblast-like type B 
synoviocytes. The sublining layer consists of scattered blood vessels, fat cells and 
fibroblasts residing in a matrix of fibrils and proteoglycans together with occasional 
mononuclear cells. When inflamed (figure 1B) the synovium undergoes profound 
changes, resulting in an increased volume and surface on macroscopic evaluation with 
accumulation of an inflammatory SF in the joint space. The lining layer becomes 
hyperplastic and forms an aggressive front termed “pannus” at the cartilage-bone 
junction, leading to the characteristic RA bone erosions. Important changes also occur 
in the sublining layer with massive mononuclear infiltration and blood vessel formation 
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[48] (figure 2). Increased joint influx and defective cell death (apoptosis) of resident 
cells are the mechanisms responsible for these cellular changes [49] and result in local 
accumulation of pro inflammatory cytokines (such as TNF). These cytokines further 
contribute to activation of synovial cells and perpetuation of chronic inflammation. The 
massive hyperplasia of the synovial membrane during inflammation does not only 
cause the majority of signs and symtoms of RA but also determines the outcome of the 
disease. 
 
 
Figure 2  
A schematic representation of a joint. A healthy joint to the left, with a thin synovial membrane, 
and an inflamed RA joint to the right, with a hypertrophied synovial membrane with massive 
influx of inflammatory cells. 
 
1.6 CELL POPULATION IN THE INFLAMED RA JOINT 
1.6.1 Monocytes/Macrophages 
Macrophages (MΦ) have phagocytic capacity and are central effectors of synovitis 
[50]. They are found both in the synovial tissue and SF. There are two types of 
macrophages in the RA synovial tissue, the macrophage-like type A synoviocytes in the 
lining and the sublining macrophages migrated as monocytes from the circulation and 
are diffusely distributed in the synovium. Both types have multiple functions like such 
as clearance of immune complexes, antigen presentation (MHC class II are 
overexpressed on MΦ), mediation and regulation of local and systemic inflammation 
and tissue remodelling through release of different cytokines and growth factors (TNF-
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α, IL-1, IL-6, IL-10, IL-13, IL-15, IL-18 and GM-CSF), mediation and regulation of 
monocyte migration and stimulation of angiogenesis by chemokines and 
chemoattractants, tissue degradation and post-injury tissue remodelling by matrix 
metalloproteinases (MMPs) [51]. They express several markers of the resident 
macrophage population including CD68, CD163 and CD14 [52]. In addition to the 
monocytes/MΦs central role in inflammation they are also involved in bone erosions 
due to their ability to differentiate into osteoclasts. Upon stimulation with TNF-α, IL-1, 
IL-6 and IL-17 synovial fibroblasts and activated T cells can upregulate RANKL 
expression on their surface which can engage its receptor RANK on the surface of 
monocytes and drive them into osteoclastogenesis [53]. Most of the macrophages in 
actively inflamed joints are localized in the synovial sublining rather than in the intimal 
lining layer [54]. Earlier studies have identified synovial sublining macrophage 
numbers as a potential biomarker for clinical efficacy in RA [55]. This was later 
confirmed in a study of synovial biopsies from 88 RA patients before and after 
treatment with different anti rheumatic drugs [50]. The validity of synovial tissue 
sublining CD 68 expression as a therapeutic biomarker has been confirmed across 
different academic centers [56]. 
 
1.6.2 Fibroblast-like synoviocytes (FLS) 
FLS are non-phagocytic mesenchymal-derived cells. They can be found both in the 
lining and sublining layers. The FLSs found in the lining layer are highly activated and 
exhibit features with aggressive invasive properties. They are important in both 
initiation and perpetuation of RA and can contribute to maintenance of chronic 
inflammation through cell–cell contact and through elaboration of soluble products. In 
response to environmental stimuli and interactions with various cell types in the 
inflamed synovium FLS can secrete several mediators like cytokines, chemokines, 
growth factors and several other proinflammatory molecules like prostaglandins and 
leukotrienes. There are many ways to activate FLS, for example through activation of 
TLRs, exposure of cytokines and ligation of integrins by matrix molecules. The 
resistance to apoptosis characterizes FLSs and they have been linked to the progressive 
destruction of articular cartilage [52]. It has recently been shown in a SCID mouse 
model of arthritis that FLSs can migrate to a distant unaffected joint and invade and 
degrade the cartilage and thereby promote articular involvement [57]. In a very recent 
study, citrullinated fibronectin (cFn) was shown to inhibit apoptosis and increase pro-
inflammatory cytokine secretion of RA FLSs [58]. This could be one possible 
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explanation for the increased number of FLSs that contribute to the hyperplasia in RA 
synovial membrane. 
 
1.6.3 T cells 
The T cells constitute around 30-50% of all cell types in the sublining and the majority 
are CD4+ with T helper (Th) 1 phenotype [52]. T cells are identified as CD3+ cells in 
the synovial tissue and are either CD4+ Th cells, CD8+ cytotoxic T cells or CD4+ 
regulatory T cells [59]. The cytokines present in the environment affect the 
differentiation of T cells towards a particular T cell lineage [60]. The Th1 subset 
mediates cellular immunity and is defined by IFNγ secretion. The Th2 is involved in 
humoral immunity and forms mainly IL-13 and IL-4, while Th17, the newest member 
of the T cell family is identified through its signature cytokine, IL-17. Th17 cells are 
important promoters of autoimmunity in RA [61]. Synovial-derived T cells have a 
phenotype that indicate chronic immune activation but express low levels of cytokines 
and show signs of anergy [60]. 
 
1.6.4 B cells 
B cells and plasma cells are mainly found in the sublining layer of synovial membrane. 
Around 5% of sublining synovial cells are B cells. The pathogenic role of B cells in 
autoimmune disorders have historically been attributed to autoantibody production that 
would drive the inflammation locally either in soluble form or as immune complexes 
[62]. B cells contribute to RA through both antibody-dependent and antibody–
independent mechanisms. Examples of antibody-independent functions are antigen 
presentation, T cell activation and polarization, organisation of other inflammatory cells 
and dendritic cell modulation. B cells display considerable phenotypic diversity [63]. 
 
1.6.5 Neutrophils 
The phagocytic neutrophils are the most numerous and most important cells in innate 
immune responses, they take up a variety of microorganisms by phagocytosis and 
efficiently destroy them in intracellular vesicles using degradative enzymes and 
different antimicrobial substances, for example different antimicrobial peptides (AMPs) 
like LL-37, which I will describe later on in the text. 
In the RA joint neutrophils are the first cells to be recruited at the sites of inflammation 
and accumulate mainly in the inflamed SF and to a lesser extent in synovial membrane 
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at the site of active destruction where they phagocyte immune complexes and release 
degrading proteases [64]. Resting peripheral blood neutrophils are relatively short 
lived, undergoing apoptosis within 12–18 h. Primed and activated neutrophils within 
tissues undergo molecular changes that extend their life span and alter their molecular 
properties, thereby allowing them to carry out many functions that have historically 
been attributed to macrophages. Delayed apoptosis, together with synthesis of 
inflammatory mediators like IL-8, TNF-α, IL-1, IL-6, IL-12, TGF-β and BLyS, and 
ability to present antigen to T cells via MHC II, makes tissue neutrophils capable of 
driving inflammatory processes. Many of the cytokines and chemokines implicated in 
RA are potent regulators of neutrophil activity (reviewed in [65]). Several recent 
reports have suggested a possible direct contribution of neutrophils in early RA 
pathophysiology and bone remodelling [66] by mediating Th17-responses [67], 
expressing PRRs [68-70], and mediating bone resorption via activating 
osteoclastogenesis [71]. To pass from the peripheral blood to the site of inflammation, 
the neutrophil adheres to the endothelial wall using selectins, integrins and adhesion 
molecules. Rolling arrest precedes transmigration through the endothelial lining of the 
blood vessel, and chemotaxis to sites of inflammation, for example the joint. (Figure 3) 
 
 
Figure 3 
Diapedesis of neutrophils. How the neutrophils pass from the peripheral blood to the site of 
inflammation. 
 
1.6.6 Dendritic cells 
DCs play an essential role in the initiation and perpetuation of inflammatory arthritis by 
presentation of arthritogenic antigens to autoreactive T cells. Through their potent 
antigen-presentation ability they stimulate naïve T cells, direct effector cells function 
and polarize the T cell repertoire towards the Th1, Th2, or Th17 phenotypes. Myeloid 
DCs (mDCs) are considered especially important in promoting synovial inflammation. 
Plasmacytoid DCs (pDCs) are recruited in RA ST and comprise an antigen presenting 
cell (APC) population that might contribute to the local inflammatory environment, 
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particularly as a result of their capacity to produce cytokines in situ such as IFN-α, IFN-
β, Il-15, Il-18 and Il-23p19 but also secondary to their potent function as stimulators of 
allogenic T cells. The number of synovial pDCs is especially increased in RA patients 
that are ACPA positive [72]. 
 
1.7 INFLAMMATORY BIOMARKERS, MEDIATORS 
1.7.1 Cytokines 
Cells can communicate and interact with each other either trough direct cell-cell contact 
or via cytokines. Cytokines are proteins secreted by the cells of innate and adaptive 
immunity and they mediate many of the functions of the cells involved in immunity. 
Many cell types may produce the same cytokines and individual cytokines often act on 
diverse cell types. They are synthesized in response to inflammatory or antigenic 
stimuli and act locally by binding to high-affinity receptors on target cells. The 
cytokines that mediate innate immunity are mainly produced by activated macrophages 
(TNF, IL-1, IL-12, IL-18, IFN-γ, type I IFNs IL-10, IL-23, IL-27). Some of these 
macrophage-derived cytokines (IL-12, IL-18, IL-23, IL-27) also modify adaptive 
immune responses. However cytokines that mediate and regulate adaptive immune 
responses are produced mainly by antigen-stimulated T cells (IL-2, IL-4, IL-13, IFN-γ, 
TGF-β) [73]. A large number of cytokines are active in the joints of patients with RA 
and they play a major role in pathogenesis [74]. 
 
1.7.1.1  TNF-α 
 
Based on synovial samples obtained from inflamed joints, tumor necrosis factor (TNF) 
was discovered as a key modulator molecule in RA for more than 20 years ago. Based 
on original studies which demonstrated elevated TNF concentrations at the sites of 
inflammation [75] it was proposed that this particular molecule drives disease 
pathology. It belongs to the TNF superfamily and consists of a protein expressed on the 
cell surface or present in a soluble form following cleavage by a protease called TNF-
α-converting enzyme [76]. Both membrane bound and soluble forms are biologically 
active. Removal of excess TNF became a therapeutic goal [77-79]. Animal studies first 
demonstrated amelioration of chronic arthritis following TNF blockade [80-82] and a 
pilot study in RA patients, using a monoclonal anti-TNF antibody, showed impressive 
clinical results [83] and opened a new therapeutic era in RA [84]. TNF-α have several 
functions: it can activate leukocytes, endothelial cells and synovial fibroblasts, induce 
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production of cytokines, chemokines, adhesion molecules and matrix enzymes; 
suppress T reg function; activate osteoclasts and resorption of cartilage and bone; 
modulating neutrophil survival [85] (reviewed in [74]). TNF also has a dual effect on 
cell survival, being able either to promote cell death or to induce pro survival genes. 
While both TNF receptors promote early cell death, only TNFR1 can delay apoptosis 
via NF-kB-controlled expression of pro-survival genes such as Bfl-1 and TRAF-1 [86]. 
 
 
Figure 4 
Simplified picture that outlines the typical TNF-α actions that are relevant to the 
pathogenesis of RA. Adapted from Brennan et al 2008 [74] 
 
1.7.1.2 Lymphotoxin α (LT-α) 
 
LT-α formerly known as TNF-β, was originally described in 1968 as a cytotoxic factor 
produced by T cells after antigenic or mitogenic stimulation [87]. In 1984, human LT-α 
was purified from a B-lymphoblastoid cell line and its structure was determined by 
classic protein- sequencing methods [88-90]. LT-α and TNF-α are 30% homologous in 
their primary amino acid sequence [91, 92]. LT-α is structurally similar to TNF-α. LTα 
is a soluble homotrimer composed of 17-kDa monomers and binds to and signals 
specifically through TNF receptors 1 and 2 (TNFR1 and TNFR2) to exert its biologic 
activities [93]. LT-α and TNF-α have many similarities but there are some distinct 
molecular and biological differences [94, 95]. The N-terminus of LT-α, unlike that of 
TNF-α, resembles a traditional signal peptide, making its conversion to a soluble form 
extremely efficient. LT-α is never found at the cell surface, a unique feature among the 
TNF superfamily members. LT-α is anchored to the cell membrane only in association 
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with membrane-bound LT-β, as LT-αβ hetero-trimers. LT-αβ is structurally distinct 
from LT-α and comprises two membrane-anchored heterotrimers, the predominant 
LTα1β2 form and a minor LTα2β1 form, both of which interact with the LT-β receptor 
(LTβR) [95]. 
LT-α is expressed by CD4+ Th 1 cells, CD8+ T-cells, NK cells, B-cells and 
macrophages [95]. LT-α has specific roles in the development and function of the 
immune system, mainly in lymphoid organ development, organization and maintenance 
of lymphoid microenvironments, host defense, and inflammation [96]. However, most 
of the evidence pointing to these roles came from genetically deficient mice and the 
relevance of LT-α in humans is less clear. In an animal model of collagen-induced 
arthritis, blocking of LT-α with a monoclonal antibody significantly improved the 
disease [97]. The main mechanism for improvement was attributed to the depletion of 
LT-α expressing Th1 and Th17 cells. Recently it has been demonstrated that LT-α can 
trigger activation of FLSs [98]. However LT-α was not detected in whole sera, plasma 
and synovial fluid of patients with RA, using commercially available ELISA kits. 
 
1.7.1.3 IL-6 
 
IL-6 is a cytokine produced by T cells, B cells, monocytes and fibroblasts, present at 
elevated levels in patients with RA. IL-6 signalling involves both a specific IL-6R and 
a ubiquitous signal-transducing protein, gp130 that is also utilized by other members of 
the IL-6 family. Il-6 signalling occurs by two mechanisms. Conventional signalling 
involves the binding of IL-6 to trans-membrane IL-6R on cells expressing this receptor. 
In contrast, trans-signalling involves binding between the complex of soluble IL-6R/IL-
6 and membrane-bound gp130. Trans signalling allows IL-6 to affect cells that do not 
express IL-6R, including many synovial cells [99, 100]. The biological activities of IL-
6 contribute to both systemic and local RA symptoms. Il-6 is a strong inducer of the 
acute-phase response, which can result in fever, secondary amyloidosis, anemia and 
elevations in acute phase proteins, such as C-reactive protein (CRP) [100]. The ability 
of IL-6 to induce B cell differentiation may lead to the formation of rheumatoid factor 
and other autoantibodies [101]. In joints, IL-6 promotes osteoclast activation and 
induces the release of MMP, thus contributing to joint damage [102, 103]. In patients 
with RA, IL-6 levels correlate with markers of disease activity and clinical symptoms. 
IL-6 signalling plays an important role in inflammatory cell migration by increasing the 
rate of cell adhesion and by inducing chemokine production in inflamed joints. [104]. 
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1.7.2 Antimicrobial peptides  
AMPs are naturally occurring peptides considered to be among the earliest developed 
molecular effectors of innate immunity [2, 3]. Two of the most extensively studied 
mammalian gene families of AMPs are the cathelicidins and the defensins [105]. The 
genes of mammalian cathelicidin consist of four exons, where exon four encodes the 
anti-microbial domain. CAMP (Cationic Anti-Microbial Peptide) is the single 
cathelicidin gene in humans. The human AMP LL-37 is a linear 37-residue peptide 
generated from the C-terminus of its precursor protein hCAP18 by a proteolytic 
cleavage [106]. 
 
1.7.2.1 LL-37 
 
LL-37 is expressed in many cell-types and stored as the precursor hCAP-18 in large 
quantities in the specific granules of neutrophils [107]. LL-37 has a direct antimicrobial 
action but also diverse immune-modulatory effects such as increased chemotaxis of 
neutrophils, monocytes and T-cells [105], activation and maturation of B-cells and 
dendritic cells [105, 107, 108] and differentiation of macrophages towards 
macrophages with a pro-inflammatory signature [109]. It is known that cathelicidins 
and other AMPs influence adaptive immunity by acting on antigen presenting cells 
(APCs). Cathelicidins are secreted and taken up by macrophages, B cells and DCs and 
their effects on these cells lead to selective immune activation [105, 110, 111]. 
Immature monocyte derived DCs transport LL-37 into the cytoplasm and nucleus 
where LL-37 acts to up regulate CD68 and HLA-DR expression [112], these markers 
are associated with activation of the adaptive immune response. 
LL-37 is produced by keratinocytes and neutrophils in wounded skin [113] and appears 
to be involved in the pathogenic events by binding locally released self-DNA and self-
RNA in psoriasis, thus forming large aggregates that are resistant to nuclease-attack 
and transport and retain the nucleic acids in the early endosomes of pDCs, thereby 
leading to extended activation of TLR-7 and TLR-9 [114, 115] and production of type I 
IFN while inhibiting TLR-3 responses [116]. Patients with SLE [117, 118] but also a 
subtype of RA patients [119] display a type I IFN signature as measured by peripheral 
blood mononuclear cells (PBMC) gene expression. Given the importance of AMPs for 
development of SLE and psoriasis, there is a possibility that AMPs could also be 
mediators in TLR-stimulated pathways leading to induction of other autoimmune 
  26 
diseases that are characterized by reactivity to nucleic acids, such as for example 
arthritis. The CAMP gene is constitutively expressed in the healthy state but can be 
increased in certain conditions, for example in psoriasis or SLE [120, 121]. 
LL-37 has also been detected as a component of the so-called NETs (neutrophil 
extracellular traps) structures that are formed following dying neutrophils. NETs 
contain self-DNA, AMPs and histones and they can serve as immunogens in SLE and 
additional autoimmune conditions by activating pDCs to produce type I IFN via TLR 
to induce a type I IFN signature [114, 122-124]. We have recently shown that LL-37 
plays a pathogenic role in mediating synovial inflammation in an animal model of 
arthritis [125]. 
 
1.8 APOPTOSIS IN RA 
Apoptosis, programmed cell death is an evolutionary conserved, multi-step process by 
which a cell dies, quietly. In contrast to necrosis the contents of the apoptotic cell are 
not released, the cell is cleared by phagocytosis and does not result in an inflammatory 
response. Apoptosis can be initiated by a variety of stimuli through different 
intracellular pathways, death receptor (DR) pathways or mitochondria-dependent 
pathways, the common link being activation of the caspases [126]. A hallmark of 
apoptosis is the degradation of DNA by cleavage between nucleosomes. To detect 
DNA strand breaks in tissues the TUNEL method, which labels DNA fragments, is 
commonly used [127]. Electron microscopy is another method frequently used; it 
identifies changes in nuclear morphology that define apoptosis [126]. 
The extrinsic pathway, the death receptor pathway is initiated through ligation of 
specific death receptors, FAS, by their ligands, FasL, TNF-related apoptosis-inducing 
ligand (TRAIL) receptors-1 and -2 and TNF receptors-1 and -2. Engagement of a death 
receptor with its ligand (e.g. FasL, TRAIL and TNF-α) induces apoptosis via activation 
of caspase-8 [128]. Fas-FasL interaction result in the recruitment of Fas associated 
death domain (FADD) and pro-caspase 8, which is cleaved to activate caspase 8. 
Activated caspase 8 either directly cleaves caspase 3 or activates BH3 interacting 
domain death antagonist (Bid), which disrupts mithocondrial integrity through the 
action of the pro-apoptotic molecules Bcl-2 associated X protein (BAX) and Bcl-2 
homologous antagonist killer (BAK). In some cells, especially MΦ, growth factor can 
activate the PI3K/PKB pathway. The phosphorylation and activation of protein kinas B 
(PKB) by PI3K (phosphatidylinositol 3-kinase) regulates the anti-apoptotic protein 
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myeloid cell leukaemia-1 (Mcl-1) and A1expression. NF-κB activated by TNF-α has 
the same effect. Mcl-1 and AP1 (activator protein 1) together with Bcl-2 maintain 
mitochondrial integrity by inhibiting the damage promoted by aggregation of BAX and 
BAK. Following the loss of mithochondrial integrity cytochrome c is released and 
together with Apaf-1 (apoptosis protease activating factor 1) and pro-caspase-9 the 
apoptosome is formed activating caspase 9 and subsequently caspase 3. Caspase-3 
promotes the characteristic features of apoptosis, including DNA fragmentation and 
cell death. Mitochondrial apoptosis might be directly induced by cytotoxic 
chemotherapy, UV irradiation, growth factor withdrawal or induction of p53 [129]. 
(Figure 5). 
 
Figure 5 
Schematic representation of apoptosis induction and suppression in RA synovial cells. (FADD: Fas 
associated death domain, TNFR: TNF receptor, NF-κB: nuclear factor κB, GFR: growth factor receptor, 
PI3K: phosphatidylinositol 3-kinase, PKB: protein kinas B FLIP: Fas-associated death domain-like IL-
1β-converting enzyme inhibitory protein, Bid: BH3 interacting domain death antagonist, tBid: truncated 
Bid, Mcl-1: myeloid cell leukaemia-1, AP1: activator protein 1, BAX: Bcl-2 associated X protein, BAK: 
Bcl-2 homologous antagonist killer Apaf-1: apoptosis protease activating factor 1) 
 
The massive hyperplasia of the synovial membrane in RA is partly due to a defective 
apoptosis of infiltrating and resident synovial cells [52]. There are several potential 
mechanisms that can explain the resistance to apoptosis in RA. Histological studies 
have demonstrated low levels of apoptosis in the RA synovial tissue [127, 130], 
between 1% and 3% of synovial cells, despite the presence of both cell death receptors 
(Fas and TNFR) and cell death ligands (Fas-ligand and TNF) in the inflamed synovium 
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[131, 132]. Neutrophils that have migrated into RA joints display a delay in apoptosis, 
and thus have an enhanced potential to mediate host tissue damage because of their 
extended life span [133, 134]. It has been suggested that this delayed apoptosis in 
neutrophils could be partially due to the hypoxic conditions in the joints [135]. The 
anti-apoptotic Mcl-1 of the Bcl-2 family is involved in the pathophysiology of 
inflammatory disorders, and has been shown to be elevated in synovial fibroblasts 
[136], macrophages [137] and lymphocytes, as well as neutrophils [135] from 
inflammatory arthritis patients. Dysregulation of the intrinsic apoptotic pathway in RA 
has been reported to occur via increased expression of BAX and Bcl-xL in 
synoviocytes [138] and B cells [139], and Bcl-2 in CD4+CD28-T-cell clones [140] and 
RA synovial tissue [141]. This may be explained by high expression of Fas-associated 
death domain-like IL-1β-converting enzyme inhibitory protein (FLIP) in synovial tissue 
[142]. FLIP inhibits caspase-8 activation by blocking its engagement with intracellular 
domains on death receptors, and expression of FLIP is under the control of Nuclear 
Factor (NF)-kB, a transcription factor that is activated by TNF-α [143].   RA-FLSs are 
relatively resistant to apoptosis and through both cell-cell interactions and the secretion 
of soluble factors they also prevent infiltrating B and T cells from undergoing apoptosis 
[144]. 
 
1.9 TREATMENT 
1.9.1 Classic anti rheumatic drugs 
While more modern therapies, such as biologicals, have been developed based on pre 
existing knowledge about disease pathogenic mechanisms, classical anti rheumatic 
drugs, such as glucocorticoids and methotrexate, have been empirically used in RA 
based on the assumption that these drugs will exert their effect through mechanisms 
described in disease states others than RA. It is therefore important to characterize the 
disease specific mechanisms of action of these drugs for a more rationale use in clinical 
practice. However surprisingly few studies are available. 
 
1.9.1.1 Methotrexate (MTX) 
 
MTX is the most frequently used disease-modifying anti-rheumatic drug (DMARD) 
and it suppresses disease activity and reduces joint damage [145]. It is usually the first 
DMARD administered to patients with RA. It should be initiated when the disease is 
first diagnosed. The dose used and escalation of dosing has increased in recent years. 
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Folic acid is given to limit toxic effects. Findings of observational studies show that 
many patients remain on methotrexate and it achieves good outcomes [146]. MTX is a 
folate antagonist but the precise mechanism of action in the treatment of RA is unclear, 
it is thought that MTX prevents de novo pyrimidine and purine syntheses, required for 
DNA and RNA syntheses, and consequently inhibits cellular proliferation of 
lymphocytes involved in the inflammation process. At the cellular level, MTX and/or 
MTX-polyglutamates directly inhibit dihydrofolate reductase (DHFR), thymidylate 
synthase (TS) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
transformylase. Other folate enzymes such as methylenetetrahydrofolate reductase 
(MTHFR) may be influenced indirectly. MTX enters the cell via the reduced folate 
carrier (RFC1), whereas several multi-resistance proteins (MRPs) and P-glycoprotein 
(P-gp) probably facilitate cellular efflux [147]. 
Methotrexate has been shown to down regulate RA synovial inflammation with a 
decrease in the number of synovial macrophages probably due to deactivation of the 
endothelium with reduced expression of cytokines [148] and adhesion molecules [149]. 
A potential beneficial effect on cartilage has been suggested by the significant down 
modulation of synovial MMPs [149, 150] and our yet unpublished data suggest also an 
effect on bone metabolism through specific decrease of synovial RANKL expression. 
Only few studies are available in other diseases than RA, namely in psoriasis arthritis, 
where methotrexate decreased inflammatory synovial infiltrates and MMP expression 
without any effect on hypervascularity, a prominent feature of this type of arthritis 
[151, 152]. 
We have recently shown that MTX directly affects the RANKL/RANK/OPG system 
and inhibits osteoclast formation, a mechanism that might explain the bone sparing 
effect observed for MTX in clinical practice (Revu, S et al, Manuscript). 
 
1.9.1.2 Glucocorticoids 
 
Glucocorticoids (GCs) are potent anti-inflammatory agents that modulate apoptosis of 
immune cells. Most studies on mechanism of action (MAO) of GCs have addressed the 
effect of systemic administration. In this respect systemic GCs decrease macrophage 
number and tends to decrease the numbers of T cells, B cells and FLSs, probably 
through down regulation of the expression of synovial chemotactic factors [153] and 
adhesion molecules [154]. As a more specific synovial consequence of systemic GC, 
up regulation of the anti inflammatory S100A8 protein has been reported [155]. Real-
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time quantitative PCR (Q-PCR) identified synovial expression of IL-8 and MMP-1 as 
biomarkers correlating with clinical response in a placebo controlled study of systemic 
GCs [156]. GC activities can be divided in genomic effects mediated through cytosolic 
glucocorticoid receptors (GRs) that need hours to become evident at the cellular and 
tissue levels and non genomic effects mediated through membrane-bound GR or 
nonspecific physicochemical interaction with the cell membrane which might explain 
some of the immediate effects observed with GC administration in vivo [157]. There 
are several synthetic GCs, such as triamcinolone hexacetonide (for local intra-articular 
administration) and methylprednisolone (for both local and systemic administration), 
used in clinical practice today. Differences in the mechanisms of action of these two 
compounds have been previously reported [158]. 
 
Few reports on the MAO of local administrated GC are available. We have previously 
demonstrated that ia GCs decrease the number of synovial T cells, whereas the number 
of macrophages remained unchanged [159]. We could also show that overall synovial 
protein expression of TNF-α, IL-1β, extranuclear HMGB-1, VEGF, and ICAM-1 was 
reduced at follow up tissue sampling, while no significant effects were observed 
regarding vascularity following ia GCs. In contrast, expression of IL-1α, VEGF, and 
cytoplasmic HMGB-1 protein in vascular endothelial cells was not affected. GC 
therapy down regulated levels of messenger RNA (mRNA) encoding IL-1α and IL-1β, 
but not TNF or HMGB-1. Synovial cell infiltration and pro-inflammatory cytokine 
expression were affected in a multifaceted manner by ia GC treatment. Marked 
reduction of synovial T lymphocytes, TNF, IL-1β, extranuclear HMGB-1, ICAM-1, 
and VEGF occurred in association with beneficial clinical effects [160]. We further 
demonstrated that GCs could change the pro bone destructive synovial phenotype 
through specific down regulation of RANKL expression [159] and modulate the 
synovial prostaglandin pathway [161]. Our group has focused on the studies of 
mechanisms of action of ia GC, an adjuvant therapy largely used in different clinical 
settings for RA treatment. 
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1.9.2 Biologicals 
1.9.2.1 TNF antagonists 
 
TNF was discovered as a key modulator molecule in RA for more than two decades 
ago. In the search for understanding the pathogenesis of RA and cytokine biology TNF 
and interleukin-1 (IL-1) emerged as key factors in inflammation. Originally studies on 
animal models of RA showed good effect of TNF blockade [80-82]. A pilot study was 
performed in RA patients using a neutralizing chimeric monoclonal anti-TNF antibody, 
cA2, now called infliximab also gave very positive results [83]. There was strong 
symptomatic response, with relief of tiredness, lethargy and morning stiffness, 
reduction of swelling and tenderness. This study was followed by a larger multicenter 
study, a double-blind placebo-controlled trial with the same antibody, performed in 
four European centres, which showed the same good results [84]. Re-treatment of eight 
patients from the first open study was also successful [162]. Today there are five TNF-
antagonists available: Infliximab, a chimeric monoclonal antibody; Etanercept, a 
recombinant TNF receptor-Fc fusion protein; Adalimumab, a fully human monoclonal 
antibody; Certolizumab, a recombinant humanized antibody Fab’ fragment; 
Golimumab, a fully human monoclonal antibody. The mechanisms of action of TNF 
antagonists have been intensively studied but still there are many questions unsolved. A 
class effect of different TNF antagonists is the decrease in synovial cellularity observed 
by immunohistochemistry for cell surface markers as early as 48 hours and maintained 
up to 2 months after treatment initiation [163, 164]. The decrease concerns mainly 
intimal and sublining macrophages and is less pronounced for plasma and T cells, 
suggesting that TNF antagonists mainly target the macrophage synovial compartment. 
Further histological examination of arthroscopic obtained synovial biopsies provided 
even insights into the mechanisms behind this change in cellularity consisting in both 
decrease expression of adhesion molecules with consecutive reduction of cell 
recruitment [165] and increased apoptosis with consecutive increase in the clearance of 
resident cells [166]. Using similar methodology, the direct and selective modulation of 
the receptor activator of the NF-kB ligand (RANKL) pathway has been proposed to be 
responsible for the bone protective effect observed with these drugs in clinical studies 
[167], while MMP modulation is thought to be important for the cartilage protective 
effects. TNF antagonists also down regulate expression of synovial and serum cytokine 
levels [168-171]. Most of the studies on the effect of TNF antagonists have been 
conducted with Infliximab-treated patients with RA. 
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1.9.2.2 Rituximab 
 
Rituximab is a chimeric monoclonal antibody directed against CD20 antigen expressed 
by B cells. Treatment of chimeric mice with anti-CD20 mAb inhibited the production 
of IFN-gamma and IL-1β, indicating that APCs other than B cells could not substitute 
in maintaining T cell activation. Different studies have shown that treatment with 
rituximab causes a rapid and specific decrease in numbers of B cells in the synovium 
after 4 weeks. The early synovial tissue response varied between patients but in the 
peripheral blood there was a marked B cell depletion in nearly all patients [172, 173]. 
Prolonged follow-up showed good clinical response and a more pronounced decrease 
of B cells after 16 weeks but also a significant decrease in sublining macrophages, T 
cells and plasma cells supporting the concept that B cells have a big role in synovial 
inflammation [56, 174-176]. 
 
1.9.2.3 Abatacept 
 
Abatacept, a CTLA4-Ig fusion protein, attenuates T cell activation as it regulates the 
activation of T cells by inhibiting the CD80/86:CD28 co-stimulatory pathway that is 
required for the proper T cell activation. Abatacept had minimal effect on synovial cell 
composition but significantly down modulated IFNγ gene expression in the inflamed 
RA synovium [177]. 
 
1.9.2.4 Tocilizumab 
 
Tocilizumab is a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, 
which binds to circulating soluble IL-6 receptor and membrane-expressed IL-6 
receptor, inhibiting IL-6 by binding to both forms of IL-6 receptor [178]. 
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2 AIMS OF THIS THESIS 
2.1 GENERAL AIM 
The overall aim of this project was to identify new molecular mechanisms responsible 
for inflammation in the rheumatoid joint and to understand how distinct anti rheumatic 
drugs interact with these mechanisms. 
 
2.2 SPECIFIC AIMS 
1. To develop and validate a standardized procedure to obtain synovial biopsies 
for further molecular studies (study I) 
2. To characterize synovial expression of LT α and TNF-α in therapy resistant RA 
and their modulation by anti TNF treatment (study II) 
1. To characterize synovial T cell apoptosis and its modulation by intra articular 
glucocorticoids in active RA (study III). 
3. To investigate a potential new role for LL-37 as a pro-inflammatory molecule 
in RA and to study its modulation by distinct anti rheumatic drugs (study IV) 
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3 RESULTS AND DISCUSSION 
The main focus of my research has been to look at the synovial membrane in RA 
patients. Arthroscopy with consecutive synovial immunohistology is a major research 
tool to dissect molecular mechanisms at the site of inflammation, without further in 
vitro manipulation, needed for fine characterization of both new and more classic anti 
rheumatic drugs. This will eventually contribute to a better use of different combination 
therapies in clinical practice and a better understanding of differences between 
therapies in terms of both effectiveness and adverse reactions. The ultimate goals of 
this type of research are identification of both new therapeutic targets and synovial 
biomarkers for predicting disease course and therapy response. 
 
3.1 PAPER I - EVALUATION OF ARTHROSCOPY AND MACROSCOPIC 
SCORING  
Safety of and yield of adequate synovial samples by arthroscopy 
We have established an arthroscopy research unit at our department since 1998 with 
408 procedures until 2005. We have validated the safety of the procedure and its 
usefulness as a research instrument. In our hands rheumatologic arthroscopy was a safe 
method with very few complications (two major and one minor complication; two 
haemarthrosis and one wound infection, respectively). Importantly, other major 
complications, such as septic arthritis or deep vein thrombosis, did not occur. In our 
study no arthroscopy procedure lasted more than one hour, and we kept the irrigation 
volume at a minimum, which might contribute to lowering the risk of infection as this 
has before been described as a risk factor for infection [40]. Despite the use of local 
anaesthesia, pain might still be a problem. In our study the physician responsible for the 
procedure notified occurrence of pain in each case, but it was not captured in a formal 
protocol. We had to prematurely terminate 12 procedures (3% of the cases) due to pain. 
In one patient the pain induced at the time of the arthroscopy lasted for two weeks. The 
large majority of the patients who were asked to do a second follow up arthroscopy 
consented to the procedure indicating that the experience of pain was low. 
 
Yield of biopsies adequate for histology was 83% over all, 94% for knee joints and 
34% for smaller joints. The low rate of adequate histology from small joints might be 
an obstacle that is possible to overcome with the right training and the use of ultrasound 
guidance [37] as other groups have reported better success rate [179]. In our case we 
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decided to restrict the studies mainly to knees, ankles and wrists if repeated biopsy 
sampling of the same joint was required. 
 
Macroscopic scoring 
There is an obvious need to correlate macroscopic findings and microscopic/molecular 
analysis of inflamed joints. Several different macroscopic scales have been used [41, 
42, 180] and have been found to correlate with molecular SM features [180, 181]. Only 
a few studies have been published on intra and inter-variation of different raters in 
macroscopic scoring. We created a method for macroscopic scoring using printed 
photographs of synovitis obtained at arthroscopy. Fifty images where scored by seven 
raters twice, regarding hypertrophy, vascularity and synovitis using a five-point scale 
(0-4). Intra-individual scoring variation was low; at the second scoring 99% of all 
scores were within one point of the first scores using a five-point scale. Further, a 
perfect match between first and second scoring sessions was reached in 70% of scores, 
and no single parameter had a substantially greater intrinsic variability. We also 
showed low inter-rater variation: 1036 of 1050 individual scores (98.7%) were within 
one point from the median score. The range was two points or less in 139 of 150 
(92.7%) image scores. 
Some of the images and scores from the first set were used to create a reliable and easy 
to use macroscopic synovial scoring system for arthroscopy (Macro-score). These 
written instructions were tested on the same set of 50 photographs by five control-raters 
with no previous experience of arthroscopy. Without any other instructions they scored 
well and the time to understand the score and perform the score was about 2- 2.5 hours. 
 
3.2 PAPER II - ETANERCEPT DECREASES SYNOVIAL EXPRESSION OF 
TUMOR NECROSIS FACTOR AND LYMPHOTOXIN-α  IN 
RHEUMATOID ARTHRITIS 
TNF-α is a key modulator of chronic inflammation in RA synovium, but less is known 
about LT-α, another pro inflammatory member of the same cytokine family. Few 
previous reports have investigated the expression in the synovium. Etanercept is the 
only TNF antagonist acting as a soluble receptor and able not only to block TNF-α but 
also LT-α, at least in vitro. High levels of expression of synovial LT-α have therefore 
been proposed as a possible mechanism to explain why certain patients might respond 
to etanercept while being resistant to treatment with TNF antagonists that exclusively 
block TNF-α such as infliximab [182]. However this original speculation has been 
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dismissed in a subsequent study demonstrating no significant differences in synovial 
baseline expression of LT-α in responders and compared to non-responders to 
infliximab. Buch et al looked at a subgroup of patients (n=5) demonstrating total failure 
to respond to infliximab but measurable clinical response to etanercept. In these 
patients there was no significant difference in expression of LT-α before treatment with 
etanercept compared with infliximab good responders (ACR 50/70) [183]. We further 
confirm this by demonstrating similar baseline expression of synovial LT-α in both 
responders and non-responders to etanercept treatment. In another study from the same 
group they could see that baseline synovial TNF-α and IL-1 expression did not predict 
infliximab response but synovial TNF-α level expression was reduced in all patients 
after infliximab treatment except for the worst non-responders [184]. Earlier it has been 
shown that TNF-α synthesis was reduced 2 weeks after infliximab treatment and that 
high level of synovial TNF-α production prior to treatment may predict responsiveness 
to therapy [168]. Another group has also showed the same results in a larger study with 
143 patients. Here they could confirm that the baseline level of TNF-α expression was a 
significant predictor of response to infliximab [185]. In a study that was originally 
designed to examine the effectiveness and safety of etanercept in RA patients that had 
failed infliximab they could show good effect of etanercept but an exploratory analysis 
of serum LT-α and anti-infliximab antibodies was also performed. That analysis did not 
show any evidence of relationship between LT-α levels and response to etanercept 
[186]. 
 
Etanercept down regulates synovial LT-α and TNF-α expression in good clinical 
responders 
To our knowledge this is the first study to investigate the effect of etanercept on 
synovial cytokine expression in relation to clinical response to therapy in RA patients. 
We demonstrate that etanercept decreases synovial expression of both TNF-α and LT-α 
and that this effect is restricted to good clinical responders. Clinical response to 
etanercept could not be predicted by differential synovial expression of these cytokines 
at baseline. We demonstrated that LT-α was present in a majority of the investigated 
RA biopsies (n=46) with large variations between different patients. LT-α was detected 
in both lining and sublining layers in a majority of patients, with high inter individual 
variations in a similar manner with other synovial cytokines [44]. Infliximab treatment 
had no effect on synovial expression of LT-α. These findings taken together suggest the 
existence of a specific and TNF-independent regulation of synovial LT-α by etanercept. 
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Another possible explanation is that the low number (etanercept n=12, infliximab 
n=11) of the patients might prevent identification of meaningful changes specifically in 
the infliximab group. However, similar numbers of patients allowed detection of 
significant changes in the etanercept group and in previous studies on infliximab [44, 
166, 167]. We observed higher baseline levels of synovial TNF-α expression in 
responders as compared to non-responders to etanercept, but the difference was not 
statistically significant. No such difference was however observed for LT-α, suggesting 
that LT-α is rather a bystander than a major driving cytokine of the rheumatoid 
synovial inflammation. 
	 
3.3 PAPER III – MONOCYTES ARE ESSENTIAL FOR INHIBITION OF 
SYNOVIAL T CELL GLUCOCORTICOID-MEDIATED APOPTOSIS IN 
RHEUMATOID ARTHRITIS 
Defective synovial apoptosis is one important mechanism contributing to local cell 
accumulation and perpetuation of inflammation in RA. RA synovial T cells express a 
phenotype suggesting chronic immune activation but have been found resistant to 
apoptosis [187, 188]. GCs are known inducers of T cell apoptosis, mainly through the 
mitochondrial pathway [189]. Our group have previously shown a decrease in the 
number of synovial tissue T cells after treatment with ia glucocorticoids in a wide range 
of arthritis types and suggested that this finding might be the consequence of reduced 
cell trafficking to the joints [160]. However apoptosis induction by GCs might be an 
additional mechanism and the aim of this study was to investigate if this was true. 
 
All patients included in the study were clinical responders as evaluated by physician 
assessment during arthroscopies. The clinical response was paralleled by a significant 
decrease in the number of ST T cells as evaluated by CD3 staining, without changes in 
the number of ST macrophages, as evaluated by both CD68 and CD163 staining. 
We confirmed low levels of apoptosis in synovial tissues obtained from active arthritis 
that were unchanged following local administration of ia injection of GCs. The 
synovial apoptosis was evaluated using TUNEL technique and staining for active 
caspase-3 and confirmed with dual-immunofluorescence CD3/TUNEL. Similar, RA SF 
T cells were resistant to GC-induced apoptosis when cultured in vitro in the presence of 
monocytes. However upon SF isolation and separate culture of T cells, apoptosis 
induction was readily detected after exposure to GCs (dexamethasone, triamcinolone 
and methylprednisolone, had all the same effect). Transwell co-culture of monocytes 
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and T cells demonstrated that soluble factor(s) and not cellular contact are essential for 
T cell resistance to GC-mediated apoptosis. It has earlier been demonstrated that 
monocytes isolated from RA SF express IL-15 [190], a cytokine able to up regulate 
Bcl-2 expression [187] and to render activated T cells resistant to glucocorticoid-
mediated apoptosis [191]. This feature appears to be RA-specific as T cell apoptosis 
induction was observed in co-cultures of cells, obtained from psoriatic arthritis patients, 
in the presence of dexamethasone at similar doses. In conclusion, we demonstrate that 
monocytes rescue synovial T cells from glucocorticoid-induced apoptosis, a feature that 
seem to be specific for RA. 
 
3.4 PAPER IV – IDENTIFICATION OF THE ANTIMICROBIAL PEPTIDE LL-
37 AS A POTENTIAL MEDIATOR OF SYNOVIAL INFLAMMATION IN 
RHEUMATOID ARTHRITIS 
LL-37 is originally described as an anti microbial peptide belonging to the cathelicidin 
family with important functions in innate immune response but recently also implicated 
as a modulator of acquired immune responses [105, 192-194]. We have recently 
reported that rCRAMP, the rat homologue of human LL-37, plays a pathogenic role as 
a local and systemic mediator of inflammation in an animal model of arthritis. This 
suggests that LL-37 may contribute to RA pathogenesis [125]. To extend these findings 
and add new knowledge on the role of LL-37 in human RA we investigated the 
expression of LL-37 in synovial membrane and its relationship to local inflammation. 
We started with a screening of LL-37 expression performing immunohistochemistry on 
different tissues from a patient with RA where we looked at bone marrow, lymph node 
and synovial biopsies. We also looked at lung biopsies from patients with RA (Figure 
6) and synovia from other arthritis like psoriatic arthritis and we could in all of the 
different tissues identify LL-37 expression. 
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Figure 6 
Immunohistochemical analysis of LL-37 expression in lungtissue from a patient with RA. LL-37 
expression in cells with neutrophil morphology (A), negative control (B). Magnification x25  
 
LL-37 was expressed in a majority of the 37 pre-treatment RA synovial biopsies, both 
in the lining and sublining layers. The peptide was also detected by western blot in the 
inflamed SF, while only low levels of LL-37 were detected in the healthy synovium.  
Treatment with adalimumab and ia GCs but not MTX resulted in a significant down-
regulation of synovial neutrophils and LL-37 expression. Using serial and double-
fluorescent immunostaining we could confirm that neutrophils and to a lesser extent 
macrophages were the main cell-types expressing LL-37. We also found LL-37 
expression in the endothelium in some of the biopsies from healthy individuals and 
following intra-articular glucocorticoids, which is intriguing and its relevance for the 
synovial biology needs further investigation. 
 
Previous studies have demonstrated that a broad spectrum of AMPs are expressed to 
different extent in normal, inflamed and pyogenic synovial membranes at both RNA 
and protein level [195]. However, synovial distribution of LL-37 has only been 
investigated at the RNA level showing that LL-37 mRNA is present in the synovial 
membranes of RA and osteoarthritis but absent in healthy and pyogenic arthritis [195-
197]. In accordance with this we here demonstrate very low levels of LL-37 expression 
on peptide level in healthy synovium and with distinct up-regulation in active RA that 
could be reverted by anti-rheumatic treatment. Similar to our current study we have 
previously shown over-expression of the rat cathelicidin rCRAMP during pristane-
induced arthritis (PIA). The induced expression was most pronounced at the very early 
phase of disease but sustained until the late, chronic stage (figure 7). 
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Figure 7 
Immunohistochemical analysis of rCRAMP expression in hind paws of Dark Agouti rats at day 0 and 23 
after pristane injection. In naïve animals (A and B) rCRAMP is expressed in synoviocytes (especially in 
the synovial lining (B with magnification x40)), part of the chondrocytes and in osteoblast-like cells of 
bone marrow. During pristane-induced arthritis (PIA) (C and D), rCRAMP is also strongly expressed in 
inflammatory cells of the infiltrating pannus tissue. Magnification x40 (D) shows strongest expression in 
cells with neutrophil morphology (blue arrow) and intermediate expression in macrophage-like cells and 
multinucleated osteoclasts (red arrow). 
 
Low level of LL-37 expression in the normal synovium and septic arthritis with up- 
regulation in the context of sterile inflammation suggests that LL-37 mainly contributes 
as mediator of the local adaptive immune response in RA, and not acting as an 
antimicrobial defensive peptide.  
LL-37 is capable of attracting various cell-types such as phagocytic leukocytes, 
immature dendritic cells, and lymphocytes, together with its capacity to stimulate IL-8 
production and mast cell degranulation offers some insights in its potential pro-
inflammatory role in arthritis [107, 198]. Recently a novel mechanism has emerged by 
which LL-37 can contribute to the generation of autoimmune diseases. It has been 
shown that in psoriatic lesions excessive LL-37 accumulates with subsequent binding 
of self-DNA and -RNA, forming large aggregates. These aggregates are resistant to 
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degradation and retained in the endosomes of pDCs, thereby leading to detrimental 
production of type I IFNs [114, 123, 124, 199]. Furthermore, in the sera of patients with 
systemic lupus erythematosus (SLE), immune complexes of AMPs and DNA forming 
neutrophil extracellular traps (NETs) trigger activation of dendritic cells. NETs can 
serve as auto-antigens to trigger B cell activation, as demonstrated by antibodies 
against AMPs [122, 123, 200]. A vast majority of the cells expressing LL-37 were 
identified as neutrophils, which are part of innate immunity and crucial for the 
pathogenic defense. These cells also have an important role in the modulation of 
several immune functions. They are the first cells to arrive at sites of inflammation 
[201] and are able to release cytotoxic components such as ROS, nitrogen species, 
AMPs, proteases and other inflammatory mediators. Neutrophils are mainly found in 
the SF of RA patients but may also be detected in the ST [65, 202]. Recently, 
neutrophils have been implicated as important mediators of the synovial inflammation 
in early stages of the disease, in a similar way as we observed in the pristane-induced 
model of arthritis in rats [125, 203]. However in our current study neutrophils and LL-
37 were up regulated in both early and long-standing RA seemingly more dependent on 
inflammation than of disease duration. Treatment with adalimumab and intra-articular 
GCs decreased both the number of neutrophils and LL-37 expressing cells, while no 
such effect was observed for methotrexate. It is tempting to speculate that this 
difference is due to different stages of the disease, with adalimumab and glucocorticoid 
treated patients both having longstanding RA while methotrexate treated patients are 
newly diagnosed with RA. However no differences in the level of expression of either 
neutrophils or LL-37 were observed among the three treatment groups and both early 
and longstanding RA had higher levels of expression as compared to healthy 
individuals. As far as changes in LL-37 expression paralleled changes in the number of 
synovial neutrophils we believe that the most obvious explanation is a decrease in the 
local synovial recruitment of neutrophils induced by adalimumab and intra-articular 
glucocorticoids. Despite previous reports suggesting that methotrexate also influence 
neutrophils functions at least in vitro we were not able to see any significant down-
regulation of synovial neutrophils following methotrexate treatment in vivo despite 
good clinical results in a majority of the patients. One additional possibility is a direct 
effect of adalimumab and intra-articular glucocorticoids on LL-37 expressing cells and 
lack of such effect for methotrexate, as suggested by our pilot screening in vitro in the 
LL-37 expressing cell line. 
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4 CONCLUSION 
In this thesis we have demonstrated that:  
• In our hands rheumatologic arthroscopy is a safe method with very few 
complications. For knee joints it is a reliable method to retrieve representative 
tissue in clinical longitudinal studies. Our results are similar to other few 
centers performing rheumatologic arthroscopies and are part of a continuous 
effort to develop international standards in this area. (Paper I) 
• We have also created an easy to use macroscopic score, that needs to be 
validated against other methodologies, which we hope will be of value in 
further developing international standards in this area (Paper I) 
• Etanercept treatment modulates synovial expression of both TNF-α and LT-α 
in vivo, an additional mechanism that explains the clinical efficacy observed 
with this drug in clinical practice (Paper II) 
• Monocytes are essential in rescuing synovial T-cells from glucocorticoid-
induced apoptosis through a soluble factor mediated mechanism, a feature that 
is specific for RA-derived synovial T-cells. We propose that this might be 
overcome by the combination of locally administrated glucocorticoids with 
monocyte-targeted therapies rather than T-cell apoptosis-inducing therapies 
(Paper III) 
• LL-37 is expressed in the inflamed rheumatoid synovial membrane and is 
modulated by distinct anti-rheumatic agents (Paper IV) 
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5 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
Synovial arthroscopy is a useful tool in investigating the site of active inflammation 
in chronic joint diseases. We have contributed with the experience of our centre to the 
available data in the field. It is important to note that in this context there are few 
Rheumatology centres around Europe currently performing arthrosocopies and 
therefore thorough validation and standardization of different procedures is highly 
needed. We have in our first paper described in detail our experience in performing 
arthroscopies and consider this an important part of the current ongoing collaboration 
between centres to achieve consensus and to eventually develop common protocols. 
This is an important task for the future as the development of new anti rheumatic 
drugs as well as the need for identification of new therapeutic and diagnostic 
biomarkers urge access to large samples of biopsy material that should be collected in 
similar ways in order to allow a meaningful analysis. One problem with clinical 
invasive studies is usually the small number of patients possible to collect, as was the 
case also in our hands. Because of this we have chosen to make use of internal 
controls where patients constitute their own controls. 
 
My thesis has also provided insight in how one should use arthroscopies and synovial 
biopsies in order to not only describe clinically the effect of various anti rheumatic 
drugs but also to map new and some time unexpected mechanisms of action of these 
drugs. The glucocorticoids failure to induce apoptosis was somewhat surprising as 
dexamethasone is used as a prototype for apoptosis induction in vitro in a large array 
of cellular systems. This added new knowledge to our current understanding on how 
lymphocytes gain important survival advantages just by interaction with other cellular 
components of the synovial inflamed joint. Also differences in results when different 
cell systems are used (biopsies versus mixed cell cultures versus single type cell 
cultures) further stress the importance of having access to systems as similar as 
possible with the in vivo situations. In this respect synovial biopsies offer one of the 
closest model to the in vivo situation. Further work is needed to map the factor(s) 
responsible for the apoptosis resistant phenotype of the synovial lymphocytes. If 
successful, such work would potentially allow identification of factors that might be 
new targets for therapeutic modulation. 
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Using same methodology as above we characterized in detail synovial expression of 
novel potentially inflammatory mediators, namely LT-α and LL-37. While some 
isolated reports on LT-α synovial distribution were published before, our study 
provides a more thorough investigation in a large number of biopsies. Despite some 
distinct modulation by etanercept, in accordance with what we were expected from in 
vitro experiments, we conclude that most probably LT-α is not a major denominator 
of the synovial inflammation in RA but merely a bystander molecule. Despite this 
being apparently a negative result it will still help us to better understand how drugs 
that have a certain cytokine inhibitory profile when studied in vitro can have a 
different clinical efficacy and safety profile in vivo. Analysing complex structures 
such as biopsies in parallel with more simplified cellular systems offers better 
possibilities in both designing new drugs and understanding the mechanisms of action 
of “classic” drugs. 
 
Recent reports on the potential relevance of the anti microbial peptide LL-37 as a 
modulator of inflammation and adaptive immunity prompted us to investigate its role 
in arthritis. Despite synovial membrane being a privileged area in terms of 
susceptibility to infections, we did not find a high expression of LL-37 in healthy 
synovium. It might be so that AMPs others than LL-37 are expressed in the joints. 
However the clear up regulation of LL-37 in context of inflammation and its specific 
down regulation by some but not all anti rheumatic therapies points to a potential 
pathogenic role for this molecule in the context of synovial inflammation. Future 
research in this area is needed. Recently it has been shown that modification of LL-37 
by the process of citrullination confers higher chemotactic activity against 
mononuclear leukocytes as compared to native LL-37, a process that might play a 
role in chronic obstructive pulmonary disorders. Preliminary data from our laboratory 
shows extensive expression of LL-37 in the lungs of patients with RA. If this is 
citrullinated or not, pro inflammatory or not, important for disease pathogenesis or 
not, remains to be demonstrated and will be a focus of future research. 
 
The studies presented in my thesis have contributed to the knowledge on how 
synovial arthroscopy can be used to study mechanisms of action of anti rheumatic 
drugs and to identify new synovial biomarkers. However much more work is needed 
in the future in order to translate this knowledge in clinical practice and to use it for 
the benefit of the patients. 
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